Buckinghamshire Healthcare NHS Trust has signed a contract with System C to implement AI-scribing through its electronic patient record.
Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial
Nature Medicine, Published online: 20 April 2026; doi:10.1038/s41591-026-04380-z
As presented at the 2026 AACR Annual Meeting: in a phase 1b trial, patients with microsatellite-stable colorectal cancer received a FAP-4-1BB ligand together with the CEA-directed T cell engager cibisatamab; the treatment was safe, and biomarker analysis showed induction of immunity in line with the biological rationale.
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
Nature Medicine, Published online: 20 April 2026; doi:10.1038/s41591-026-04365-y
As presented at the 2026 AACR Annual Meeting, in a phase 2 trial, treatment of patients with high-risk smoldering multiple myeloma with BCMA-targeting CAR T cell therapy ciltacabtagene autoleucel was safe and led to encouraging rates of clinical responses.
Microbiome signature of Parkinson’s disease in healthy and genetically at-risk individuals
Nature Medicine, Published online: 20 April 2026; doi:10.1038/s41591-026-04318-5
Microbiome analysis suggests that gut microbial changes in Parkinson’s disease evolve progressively from healthy individuals to genetically at-risk individuals to clinically affected patients, with the degree of dysbiosis correlating with disease progression.
[Comment] The unattributable burden of disease
Non-communicable diseases remain the leading cause of mortality and disability worldwide and account for most health loss in high-income countries, including Italy.1 Cardiovascular diseases, cancers, diabetes, and chronic respiratory diseases are largely driven by modifiable behavioural, metabolic, and environmental exposures.2 Characterising the distribution of these risk factors and quantifying their contribution to population health is central to modern epidemiology and public health.
[Comment] Can multimorbidity research progress from description to intervention?
The concept of multimorbidity, the co-occurrence of two or more long-term conditions, has become an important focus for research in the burden of ill-health associated with ageing. A burgeoning literature shows that the prevalence of multimorbidity is substantial, even though estimates vary according to definition and method of ascertainment.1 Not many studies have taken a longitudinal approach and evaluated the incidence of multimorbidity. In The Lancet Public Health, Eirion Slade and colleagues2 report on the incidence of multiple long-term conditions, also known as multimorbidity, in an electronic health records dataset for nearly the whole of England, UK.
[Editorial] An opportunity to confront multimorbidity
The notion of compression of morbidity was the guiding principle of public health a generation ago. If one could postpone the onset of chronic disease and disability to a later age, the total lifetime burden of illness could be reduced, compressing it into a shorter period at the end of life. The goal was to increase not only lifespans, but also healthspans. Public health systems are designed to enable individuals to live long, healthy lives, before experiencing a brief, sudden decline in their final months.
[Comment] The potential of online alcohol interventions for older adults
The adverse effects of high levels of alcohol consumption on cognitive function have been documented, including using Mendelian randomisation.1 Maintaining cognitive function is a priority for individuals as they age. However, the increasing size and health needs of the ageing population globally brings challenges for provision of preventive and therapeutic interventions.
[Comment] Achieving equity requires investment in vulnerable populations
It is well known that both mental health conditions (MHCs)1 and low income2 increase the risk for communicable and non-communicable diseases. However, previous studies have not comprehensively investigated potential interactions in the effects of mental disorders and income on physical health. In their Article, Linda Ejlskov and colleagues assessed the risks of a broad range of physical health conditions (PHCs) across income strata in people with and without MHCs.3 According to their results, MHCs and low income seem to operate as independent, additive risk factors, with some notable exceptions.
CleanAssure Launched as an ISO Class 5 Controlled Cleanroom for Sterile Single-Use Assemblies
Freudenberg Medical, a Kaiserslautern, Germany-based contract design manufacturing partner, launched CleanAssure, a new ISO Class 5 controlled cleanroom designed to deliver clean and sterile single-use assemblies for biopharmaceutical customers, according to the company.
Freudenberg Medical manufactures silicone and thermoplastic elastomer (TPE) tubing for bioprocessing and critical fluid transfer. The company specializes in seamless, overmolded single-use assemblies used in vaccine production, cell cultivation, fluid transfer, and fill-finish operations.
The controlled cleanroom enables customers to receive ready-to-use washed, dried, and gamma sterilized single-use assemblies with the highest product quality, sterility, and process consistency, noted Rudi Gall, vp, global pharma, Freudenberg Medical.
“CleanAssure allows us to support our customers beyond component manufacturing,” he said. “By integrating controlled cleaning and sterilization into our single-use assembly services, we help reduce contamination risk, streamline validation activities, and support a reliable supply for our customers. We can now support customers with their entire component value chain and allow them to focus on their core manufacturing capability.”
Freudenberg’s cleaning process uses ultrapure water and air, operating within ISO 5 conditions. The water is produced using a multi-stage filtration process, resulting in high-purity water specifically suitable for pharmaceutical applications.
Key biopharma industry challenges
Biopharmaceutical manufacturers increasingly rely on single-use systems but face ongoing challenges related to cleaning validation, contamination risk, and production downtime. Customer-managed cleaning processes are often time-intensive, costly, and require additional resources while directly impacting supply reliability, according to Gall.
The company explained that its controlled cleaning environment addresses these challenges by reducing cross-contamination risk through tightly controlled ISO Class 5 processing; alleviating customer cleaning validation burden by delivering assemblies washed and sterilized under cGMP, validated conditions; minimizing production downtime by removing cleaning as a process step; and supporting a consistent, reliable supply of high-quality single-use assemblies.
Freudenberg will be attending INTERPHEX New York, April 21–23, Booth 1673, to exhibit its new products and services.
The post CleanAssure Launched as an ISO Class 5 Controlled Cleanroom for Sterile Single-Use Assemblies appeared first on GEN – Genetic Engineering and Biotechnology News.